Heparin medicine for early slow fetal growth in one pregnancy
Part of Genetic & congenital, Women’s health & pregnancy clinical trials.
This study tests whether a blood-thinner medicine (LMWH) can improve outcomes for people carrying a singleton baby with early signs of slow growth. It compares LMWH against standard care to see if treatment helps the baby and pregnancy stay safer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old and can give consent
- You are pregnant with one baby (not twins or more)
- Your early baby-growth problem was confirmed at the study site using ultrasound criteria
- You are not already taking LMWH or the related blood thinner for this pregnancy
- You do not have certain bleeding risks or bleeding conditions right now
- You likely will not deliver in the next 7 days
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how early, slow fetal growth is managed during pregnancy. It compares an “angiogenic factors” approach with an ultrasound (blood-flow) approach to help guide care and improve outcomes.
This study looks at therapies meant to support brain development in babies whose growth is slower than expected before birth. It enrolls pregnancies in a specific time window and uses ultrasound/Doppler testing to make sure the baby is not likely needing delivery immediately.
This study aims to better predict fetal growth restriction (when a baby doesn't grow as expected) in women who have certain risk factors. By joining, you may help doctors develop better screening tools for future pregnancies.
This trial studies whether taking melatonin during pregnancy can help protect the baby’s brain and organs in cases of poor fetal growth. It focuses on pregnancies at a specific gestational age with signs that the placenta may not be working well.
This trial tests whether a blood-thinning medication, enoxaparin, can improve outcomes for babies diagnosed with intrauterine growth restriction (poor growth) and too little amniotic fluid. It aims to see if treatment leads to better health for the baby at birth.
This study looks at how people’s blood and clotting behave during pregnancy when taking a specific blood thinner called low molecular weight heparin (LMWH) three times a day. It may help doctors fine-tune how safely and effectively LMWH is used during pregnancy.
Hear when a new Fetal Growth Retardation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.